AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...
Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...
This week, one Waltham biotech announced a deal to work with AbbVie that will pay out $52M upfront, while another one made ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.
Xilio Therapeutics shares took flight in premarket trading Wednesday after the clinical-stage biotechnology company formed a potentially lucrative collaboration with AbbVie that includes an equity ...
The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback